Literature DB >> 35298818

Structural Prediction of Peptide-MHC Binding Modes.

Marta A S Perez1,2,3, Michel A Cuendet3,4, Ute F Röhrig3, Olivier Michielin5,6, Vincent Zoete7,8,9.   

Abstract

The immune system is constantly protecting its host from the invasion of pathogens and the development of cancer cells. The specific CD8+ T-cell immune response against virus-infected cells and tumor cells is based on the T-cell receptor recognition of antigenic peptides bound to class I major histocompatibility complexes (MHC) at the surface of antigen presenting cells. Consequently, the peptide binding specificities of the highly polymorphic MHC have important implications for the design of vaccines, for the treatment of autoimmune diseases, and for personalized cancer immunotherapy. Evidence-based machine-learning approaches have been successfully used for the prediction of peptide binders and are currently being developed for the prediction of peptide immunogenicity. However, understanding and modeling the structural details of peptide/MHC binding is crucial for a better understanding of the molecular mechanisms triggering the immunological processes, estimating peptide/MHC affinity using universal physics-based approaches, and driving the design of novel peptide ligands. Unfortunately, due to the large diversity of MHC allotypes and possible peptides, the growing number of 3D structures of peptide/MHC (pMHC) complexes in the Protein Data Bank only covers a small fraction of the possibilities. Consequently, there is a growing need for rapid and efficient approaches to predict 3D structures of pMHC complexes. Here, we review the key characteristics of the 3D structure of pMHC complexes before listing databases and other sources of information on pMHC structures and MHC specificities. Finally, we discuss some of the most prominent pMHC docking software.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Databases; Docking algorithms; Immune system; Ligand binding; Major histocompatibility complex; Molecular mechanics; Peptide antigen; Peptide docking; T-cell receptor

Mesh:

Substances:

Year:  2022        PMID: 35298818     DOI: 10.1007/978-1-0716-1855-4_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  119 in total

Review 1.  The MHC class I antigen presentation pathway: strategies for viral immune evasion.

Authors:  Eric W Hewitt
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 2.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

Review 3.  MHC class I antigen presentation: learning from viral evasion strategies.

Authors:  Ted H Hansen; Marlene Bouvier
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

Review 4.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

Review 5.  Personalized vaccines for cancer immunotherapy.

Authors:  Ugur Sahin; Özlem Türeci
Journal:  Science       Date:  2018-03-23       Impact factor: 47.728

Review 6.  Harnessing the power of the immune system to target cancer.

Authors:  Gregory Lizée; Willem W Overwijk; Laszlo Radvanyi; Jianjun Gao; Padmanee Sharma; Patrick Hwu
Journal:  Annu Rev Med       Date:  2012-10-22       Impact factor: 13.739

7.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

Review 8.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 9.  Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?

Authors:  Thomas C Wirth; Florian Kühnel
Journal:  Front Immunol       Date:  2017-12-19       Impact factor: 7.561

Review 10.  MHC class II proteins and disease: a structural perspective.

Authors:  E Yvonne Jones; Lars Fugger; Jack L Strominger; Christian Siebold
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

View more
  1 in total

1.  Physicochemical Heuristics for Identifying High Fidelity, Near-Native Structural Models of Peptide/MHC Complexes.

Authors:  Grant L J Keller; Laura I Weiss; Brian M Baker
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.